๐ฌIn plain words
What the trial is, and whether it could suit you
This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.
Sign in to get the eligibility rules as simple questions to take to your doctor.
๐ Eligibility rules (as published)
Inclusion Criteria:
* Aged 18 to 25 years, inclusive
* Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment
Exclusion Criteria:
* Self-reported or medically-documented significant medical or psychiatric condition that per medical assessment could interfere with study participation
* Likely or confirmed myocarditis or pericarditis
* Prior receipt of an investigational EBV vaccine
* Prior receipt of a licensed vaccine within 56 days prior to Day 1
* Received more than 10 days of any systemic immunosuppressants or cytotoxic medications within 56 days prior to Day 1, any within 14 days prior to Day 1, or will need immunosuppressants at any time during the study.
* For participants of childbearing potential: pregnant, breastfeeding or planning to become pregnant during the study
Note: Other inclusion and exclusion criteria apply.
Q-Pharm Pty Ltd/Nucleus Network Pty Ltd
Herston, Australia
Nucleus Network Pty Ltd
Melbourne, Australia
๐ค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ always decide together with your own doctor.